(Q37249978)

English

ErbBs in lung cancer

scientific article published on 06 August 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

ErbBs in lung cancer (English)

1 reference

Europe PubMed Central

19 August 2017

1 reference

based on heuristic

inferred from title

author name string

Sreenath V Sharma

1

1 reference

Europe PubMed Central

19 August 2017

Jeffrey Settleman

2

1 reference

Europe PubMed Central

19 August 2017

language of work or name

0 references

publication date

6 August 2008

1 reference

Europe PubMed Central

19 August 2017

Experimental Cell Research

1 reference

Europe PubMed Central

19 August 2017

315

1 reference

Europe PubMed Central

19 August 2017

4

1 reference

Europe PubMed Central

19 August 2017

557-571

1 reference

Europe PubMed Central

19 August 2017

The new World Health Organization classification of lung tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer : a realistic goal?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Epidermal growth factor receptors in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Autocrine growth stimulation by transforming growth factor-alpha in human non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Production of epidermal growth factor related ligands in tumorigenic and benign human lung epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

New model of ErbB-2 over-expression in human mammary luminal epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Structure-based view of epidermal growth factor receptor regulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Activation of AKT kinases in cancer: implications for therapeutic targeting

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

AKT/PKB signaling: navigating downstream

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Cancer. Addiction to oncogenes--the Achilles heal of cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Lung cancer: intragenic ERBB2 kinase mutations in tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

EGFR and erbB2 mutation status in Japanese lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

ErbB4 expression and mutation in Japanese patients with lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Getting to the stem of chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Strategies to overcome resistance to targeted protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the hum

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

The shadow of death on the MET tyrosine kinase receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Epidermal growth factor receptor targeting in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Her2-targeted therapies in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Mouse models for human lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Mouse models of human non-small-cell lung cancer: raising the bar.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Identification of bronchioalveolar stem cells in normal lung and lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

EGFR gene mutations: a call for global x global views of cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Estrogen receptor signaling pathways in human non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Estrogen Metabolism and Excretion in Oriental and Caucasian Women

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Polymorphisms associated with circulating sex hormone levels in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Hormone replacement therapy is associated with decreased survival in women with lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2008.07.026

7 January 2021

Identifiers

10.1016/J.YEXCR.2008.07.026

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37249978&oldid=2095449505"